-The Indian Express The Supreme Court on Tuesday stayed its September 2012 ruling that "only" serving and retired judges of the apex court and chief justices of state high courts can head the central and state information commissions. Passing an interim order pending its decision on the review petition filed by the Centre against the verdict, a bench led by Justice A K Patnaik stayed the direction making it mandatory for information...
More »SEARCH RESULT
Total Matching Records found : 4074
Social Justice
KEY TRENDS • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8 • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...
More »Why is Aadhaar being shoved down our throats?-R Jagannathan
-First Post Electoral logic is driving the UPA towards a patent illegality: forcing people to part with sensitive private information such as biometric data or finger-prints without having any law to protect privacy in place. As things stand, getting yourself an Aadhaar card issued by the Unique Identification Authority of India (UIDAI) is voluntary; you are not legally bound to part with this information to anyone, leave alone the UIDAI ....
More »Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy
-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »SC’s Novartis judgement renews focus on accessible medicine
The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...
More »
